At HLTH 2025, Ian Khan sits down with Jenna DiRito, co-founder and COO of Revalia Bio, to discuss the future of drug development. Revalia Bio tests drugs and devices on recovered human organs, aiming to replace animal models and de-risk development with human data earlier in the process. DiRito shares how a human-data trial platform can make drug development faster and more predictive. The conversation explores how testing on real human tissue could reshape biomedical research.